Sibannac Backs Trump Order on Psychedelic Research
Sibannac Welcomes Accelerated Federal Research Order for Psychedelic Compounds
April 23, 2026
In short: Sibannac (OTCID:SNNC) benefits from a U.S. presidential executive order accelerating research into ibogaine, MDMA, psilocybin and related compounds.
Sibannac announced it will accelerate federal research into ibogaine, MDMA, psilocybin and related compounds following a presidential executive order on April 23, 2026. The company highlighted private-sector market models estimating a $5–$15 billion psychedelic-assisted wellness tourism market by 2030, targeting veterans, law enforcement and first responders as a 10–25% segment. Management stated faster research will position Sibannac to capitalize on emerging wellness tourism opportunities.
TMCs managing veteran and first responder accounts should monitor Sibannac’s accelerated research program, as it may create new demand for psychedelic-assisted wellness services in their portfolios. The company’s focus on veterans and first responders aligns with emerging market segments, suggesting potential partnership or collaboration opportunities.
What is Sibannac’s accelerated research program?
Sibannac will fast-track federal research into ibogaine, MDMA, psilocybin and related compounds following a presidential executive order.
Which travel trade segments does this affect?
TMCs managing accounts for veterans, law enforcement, and first responders are most directly impacted by this development.
When does this take effect?
The executive order was issued on April 23, 2026, and the research acceleration is expected to commence shortly thereafter.
Read complete article.
Boutique Travel VC raises investment cap from $1.5M to $10M to lead rounds and support portfolio companies through growth Travel...
Read moreDetails
